Bufalin derivative BF211 inhibits proteasome activity in human lung cancer cells in vitro by inhibiting β1 subunit expression and disrupting proteasome assembly
Cited by 23
Related Papers
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
|The Lancet Oncology|2012|541
Predict potential drug targets from the ion channel proteins based on SVM
|Journal of Theoretical Biology|2009|45